Stephanie J. Schrag
YOU?
Author Swipe
View article: Causes and risk factors for deaths in young infants in South Asia: the ANISA prospective population-based observational cohort study
Causes and risk factors for deaths in young infants in South Asia: the ANISA prospective population-based observational cohort study Open
Introduction Strategies for reducing infant mortality require accurate, local, population-level data. We conducted a population-based observational study in three countries in South Asia to describe risk factors, causes and rates of mortal…
View article: A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction
A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction Open
View article: Serum-equivalency comparison, detection, and quantification of Group B <i>Streptococcus</i> anti-capsular polysaccharide antibodies from dried blood spots
Serum-equivalency comparison, detection, and quantification of Group B <i>Streptococcus</i> anti-capsular polysaccharide antibodies from dried blood spots Open
A standardized multiplex immunoassay (MIA) to quantify group B Streptococcus (GBS) anti-capsular polysaccharide (CPS) IgG serum concentrations was adopted by the Group B Streptococcal Assay Standardization (GASTON) consortium as a s…
View article: Mucosal boosting increases protective efficacy of an influenza vaccine in mice
Mucosal boosting increases protective efficacy of an influenza vaccine in mice Open
Influenza virus infection is a significant cause of global mortality. However, the development of influenza vaccines that induce robust immune responses at the site of respiratory mucosal exposure has proven challenging. Here, we assessed …
View article: The epidemiology of bacterial meningitis in the United States during 2008–2023: an analysis of active, laboratory, population-based, multistate surveillance data
The epidemiology of bacterial meningitis in the United States during 2008–2023: an analysis of active, laboratory, population-based, multistate surveillance data Open
View article: Epidemiology of Group B <i>Streptococcus</i>: Maternal Colonization and Infant Disease in Kampala, Uganda
Epidemiology of Group B <i>Streptococcus</i>: Maternal Colonization and Infant Disease in Kampala, Uganda Open
Background Child survival rates have improved globally, but neonatal mortality due to infections, such as group B Streptococcus (GBS), remains a significant concern. The global burden of GBS-related morbidity and mortality is substantial. …
View article: 589. Late Onset Invasive Group B Streptococcal Disease Outbreak in a Neonatal Intensive Care Unit Identified Through Whole Genome Sequencing — Connecticut, 2020–2024
589. Late Onset Invasive Group B Streptococcal Disease Outbreak in a Neonatal Intensive Care Unit Identified Through Whole Genome Sequencing — Connecticut, 2020–2024 Open
Background Group B Streptococcus (GBS) is a major cause of neonatal sepsis. Outbreaks of GBS late-onset disease (LOD), defined as infection during the first 7–89 days of life, are uncommon. In September 2023, 4 GBS LOD cases were reported …
View article: Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial Open
US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases, and National Institutes of H…
View article: Association of clinical signs of possible serious bacterial infections identified by community health workers with mortality of young infants in South Asia: a prospective, observational cohort study
Association of clinical signs of possible serious bacterial infections identified by community health workers with mortality of young infants in South Asia: a prospective, observational cohort study Open
Bill and Melinda Gates Foundation, New Venture Fund for Global Policy and Advocacy.
View article: Serum-equivalency Comparison, Detection, and Quantification of Group B Streptococcus Anti-capsular Polysaccharide Antibodies from Dried Blood Spots
Serum-equivalency Comparison, Detection, and Quantification of Group B Streptococcus Anti-capsular Polysaccharide Antibodies from Dried Blood Spots Open
A standardized multiplex immunoassay (MIA) to quantify group B Streptococcus (GBS) anti-capsular polysaccharide (CPS) IgG serum concentrations was adopted by the Group B streptococcal Assay Standardization (GASTON) consortium as a standard…
View article: Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides
Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides Open
Measurement of IgG antibodies against group B streptococcus (GBS) capsular polysaccharide (CPS) by use of a standardized and internationally accepted multiplex immunoassay is important for the evaluation of candidate maternal GBS vaccines …
View article: <i>Notes from the Field:</i> Update on Pediatric Intracranial Infections — 19 States and the District of Columbia, January 2016–March 2023
<i>Notes from the Field:</i> Update on Pediatric Intracranial Infections — 19 States and the District of Columbia, January 2016–March 2023 Open
In May 2022, CDC began an investigation of a possible increase in pediatric intracranial infections, particularly those caused by Streptococcus bacteria, during the preceding year (1).January 2016-May 2022 data from a large, geographically…
View article: Higher body mass index after intrapartum antibiotic exposure in children persists over 10‐years
Higher body mass index after intrapartum antibiotic exposure in children persists over 10‐years Open
Summary Exposure to intrapartum antibiotic prophylaxis to reduce perinatal group B streptococcal disease was associated with increased childhood body mass index (BMI) persisting to age 10 years compared to no exposure (Δ BMI at 10 years: v…
View article: Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death
Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death Open
Importance Neonatal sepsis is a leading cause of neonatal mortality. New interventions are needed to decrease neonatal sepsis and mortality in regions with highest burden. Objective To evaluate the efficacy of intrapartum azithromycin to r…
View article: Still Looking for a Simple, Effective Prevention Measure for Neonatal Sepsis in High-Mortality Settings
Still Looking for a Simple, Effective Prevention Measure for Neonatal Sepsis in High-Mortality Settings Open
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Sum…
View article: Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014–2020
Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014–2020 Open
Background Descriptions of changes in invasive bacterial disease (IBD) epidemiology during the coronavirus disease 2019 (COVID-19) pandemic in the United States are limited. Methods We investigated changes in the incidence of IBD due to St…
View article: NVX-CoV2373 Efficacy in Preventing SARS-CoV-2 Infection in Adolescents
NVX-CoV2373 Efficacy in Preventing SARS-CoV-2 Infection in Adolescents Open
View article: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 Open
On September 1, 2022, bivalent COVID-19 mRNA vaccines, composed of components from the SARS-CoV-2 ancestral and Omicron BA.4/BA.5 strains, were recommended by the Advisory Committee on Immunization Practices (ACIP) to address reduced effec…
View article: Risk factors for community-acquired bacterial infection among young infants in South Asia: a longitudinal cohort study with nested case–control analysis
Risk factors for community-acquired bacterial infection among young infants in South Asia: a longitudinal cohort study with nested case–control analysis Open
Objective Risk factors predisposing infants to community-acquired bacterial infections during the first 2 months of life are poorly understood in South Asia. Identifying risk factors for infection could lead to improved preventive measures…
View article: Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States Open
Importance Pregnant people are at high risk for severe COVID-19 but were excluded from mRNA vaccine trials; data on COVID-19 vaccine effectiveness (VE) are needed. Objective To evaluate the estimated effectiveness of mRNA vaccination again…
View article: Pediatric Brain Abscesses, Epidural Empyemas, and Subdural Empyemas Associated with <i>Streptococcus</i> Species — United States, January 2016–August 2022
Pediatric Brain Abscesses, Epidural Empyemas, and Subdural Empyemas Associated with <i>Streptococcus</i> Species — United States, January 2016–August 2022 Open
In May 2022, CDC learned of three children in California hospitalized concurrently for brain abscess, epidural empyema, or subdural empyema caused by Streptococcus intermedius. Discussions with clinicians in multiple states raised concerns…
View article: Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study
Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study Open
View article: Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021 Open
View article: Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March–April 2021
Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March–April 2021 Open
In April 2021, we assessed mRNA vaccine effectiveness (VE) in the context of a COVID-19 outbreak in a skilled nursing facility. Among 28 cases, genomic sequencing was performed on 4 specimens on 4 different patients, and all were classifie…
View article: Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron Open
Effectiveness of Homologous and Heterologous Covid-19 Boosters against OmicronTo the Editor: For persons who received a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson-Janssen) against coronavirus disease 2019 (Covid-19), a boost…
View article: Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance Open
Among children and adolescents, estimated VE for 2 doses of BNT162b2 against symptomatic infection was modest and decreased rapidly. Among adolescents, the estimated effectiveness increased after a booster dose.
View article: mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients
mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients Open
Background The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods We conduct…
View article: Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 Open
CDC recommends that all persons aged ≥18 years receive a single COVID-19 vaccine booster dose ≥2 months after receipt of an Ad.26.COV2.S (Janssen [Johnson & Johnson]) adenovirus vector-based primary series vaccine; a heterologous COVID-19 …
View article: Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study Open
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the effectiveness of mRNA vaccines to prevent hospital admissio…
View article: Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 Open
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose …